Latest European Markets News

Little Green Pharma Ltd is set to acquire Cannatrek Ltd in a transformative merger that will create one of the largest vertically integrated medicinal cannabis companies globally, with pro-forma FY25 revenue exceeding AUD 112 million.

Acadia Pharmaceuticals has received a negative vote from the European Medicines Agency’s committee on its application to market trofinetide for Rett syndrome in the EU, prompting plans for a re-examination request.

Evion Group has bolstered its cash reserves to $2.3 million following a strategic placement and secured a $1.5 million expandable graphite sales agreement in the US, while advancing its Maniry Graphite Project in Madagascar with strong EU backing.

International Graphite Limited has secured key approvals and funding to progress its Collie Micronising Facility and European Expandable Graphite Project, positioning itself as a major supplier outside China.

Cann Group Limited has reported its first-ever free cash flow positive quarter, following a significant debt restructuring and a $9 million capital raise. Despite a softer quarterly revenue, the company is advancing new product launches and export partnerships, positioning itself for growth.

OncoSil Medical has reported a record quarter for dose sales alongside key European market entries and a successful manufacturing milestone, signalling growing momentum for its pancreatic cancer treatment.

Yugo Metals has made promising progress with diamond drilling at its Sinjakovo project, intersecting silver-zinc-lead mineralisation, while securing $3.5 million in new funding and expanding its investor reach through a dual listing in Germany.

Jupiter Mines reported a modest rise in manganese production and sales for Q2 FY2026, alongside lower production costs. However, earnings were dented by foreign exchange losses amid a stronger South African Rand.

Little Green Pharma reports record quarterly revenue and announces a transformative merger with Cannatrek, creating a leading vertically integrated medicinal cannabis group with strong European growth prospects.

Bioxyne Limited has reported a record $17.2 million in quarterly revenue, driven by strong growth in its cannabis and psychedelics segments, alongside strategic international expansions including a Frankfurt dual listing and new manufacturing agreements.

Memphasys has secured CE Mark approval for its Felix™ sperm selection system, enabling full commercial rollout across Europe and activating multi-year contracts worth over A$1.3 million. This milestone signals the company’s transition into a revenue-scaling phase with global growth ambitions.

CPP Investments and Goodman Group have launched a A$14 billion partnership to develop data centres across key European markets, marking CPP’s first foray into European digital infrastructure.